Full-Time

Head of Lifecycle Management Optical Devices

m/f/x

Posted on 12/13/2025

Zeiss

Zeiss

1,001-5,000 employees

Manufactures high-precision optical instruments and devices

No salary listed

Jena, Germany

In Person

Main work location is Jena with regular travel to Oberkochen.

Category
Product (1)
Requirements
  • A successfully university degree in business management or engineering – preferably with a focus on electronics or medical technology.
  • At least several years of professional experience in project management.
  • Experience in the medical technology field.
  • In-depth understanding of business operations within a matrix organisation.
  • Experience in the disciplinary leadership of project teams.
  • Experience in change management.
  • An independent working style, teamwork skills, and a high level of moderation, presentation, and communication skills.
  • Very good organizational skills and relevant experience in program management or project management (preferably with GPM Level B/C or PMI).
  • Exceptional English and German communication skills, both spoken and written.
  • Please note main work Location for this role will be Jena with regular travels to Oberkochen.
Responsibilities
  • Ensures the availability of the entire product portfolio of the product family optical devices by initiating and coordinating all necessary activities to maintain the availability, the conformity, and the competitiveness of the products in all markets during the lifecycle of the products.
  • Steer and coordinate all lifecycle programs and activities for the product family on a global level and through all sites of the product group (DE, US, CN).
  • Define and steer budget in alignment with all relevant stakeholders such as SBU, Business Sectors and Group Functions (e. g. Regulatory Affairs and Quality Management).
  • Design and implement integrated management of the Lifecycle Management programs and project landscape, including budget and resource requirements.
  • Manage and coordinate respective programs and projects through governance rules, standards and processes, methodologies and tools.
  • Continuous improvement of lifecycle management organization, including all involved parties.
  • Lead, coach and develop team members to maximize their potential, attract and retain potentials in the company.
  • Be a role model, develop, coach and trust employees.
Desired Qualifications
  • None

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • NMPA approval accelerates ARTEVO 750/850 sales in China's ophthalmic market.
  • Collaborative Care app boosts data sharing, capturing digital health interoperability growth.
  • CALYPSO 2024 software upgrade generates recurring revenue from CMM customers.

What critics are saying

  • TSMC and Samsung capex cuts collapse Semiconductor Manufacturing Technology revenue.
  • Suoer and Kangyang erode ARTEVO pricing in saturated Chinese microscope market.
  • CLINIC 360 FDA delays stall AI diagnostic platform commercialization.

What makes Zeiss unique

  • ZEISS leads in AI-powered ophthalmic tools like VisioGen and ARTEVO microscopes.
  • Balanced revenue across semiconductor, medical, industrial, and consumer optics segments.
  • 175-year legacy drives precision innovations in four global business segments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

PR Newswire
Apr 2nd, 2026
ZEISS unveils AI-powered patient platform and enhanced IOL tools at ASCRS

ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.

PR Newswire
Mar 24th, 2026
ZEISS expands ophthalmic portfolio in Canada with new diagnostic lasers and workflow tools

ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.

PR Newswire
Feb 23rd, 2026
ZEISS launches Collaborative Care app for eye care professionals with cloud and on-premises options

ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.

Handelsblatt
Feb 19th, 2026
Custom Surgical raises $4M to develop AI-powered ophthalmology platform

Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.

Investors Hangout
Feb 18th, 2026
Mindpeak raises $15.3M Series A to scale AI cancer diagnostic tools

Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.

INACTIVE